A cyano compound, its preparation method and use

By designing cyano compounds based on the 3CL protease structure, the inefficiency problem of existing anti-coronavirus and small RNA virus treatment methods is solved, effective inhibition of multiple viruses and broad-spectrum antiviral activities are achieved, and new treatments are provided plan.

CN117209555BActive Publication Date: 2024-12-03SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311097958.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2022-08-15
Filing Date
2022-09-29
Publication Date
2024-12-03
Estimated Expiration
2042-09-29

AI Technical Summary

Technical Problem

The existing anti-coronavirus and small RNA virus treatments lack high efficiency, especially the treatment of enterovirus 71, and the broad-spectrum activity of existing 3CL protease inhibitors is limited.

Method used

A class of cyano compounds was designed, based on the crystal structure of 3CL proteases, which can effectively inhibit the 3CL protease activity of coronavirus and small RNA viruses, and are used to prepare drugs for the prevention and treatment of related diseases.

Benefits of technology

This cyano compound can inhibit the replication of a variety of small RNA viruses in vitro and cellular levels, showing broad-spectrum anti-coronavirus activity, and provides effective inhibition of coronaviruses including SARS-CoV, MERS-CoV and enterovirus 71, including SARS-CoV and MERS-CoV, and enterovirus 71. Effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117209555B_ABST
    Figure CN117209555B_ABST
Patent Text Reader

Abstract

The present invention provides a compound of formula I, its racemate, enantiomer, diastereomer and pharmaceutically acceptable salt, and its use in preventing or treating diseases related to coronavirus and / or small RNA virus infection. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with application number 2022800054540 (international application number: PCT / CN2022 / 122384), application date September 29, 2022, and invention name “A class of cyano compounds, preparation methods and uses thereof”. Technical Field

[0002] The present invention belongs to the field of pharmaceutical chemistry and chemical synthesis, and in particular, relates to a class of cyano compounds, preparation methods and uses thereof. Background Art

[0003] Coronaviruses are single-stranded positive-sense RNA viruses, some of which can spread widely among people and cause severe symptoms. Currently, there are seven known coronaviruses that can infect humans, namely HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2. Most of the functional proteins of coronaviruses are encoded by the ORF1ab gene, which is first translated into a polyprotein and then cleaved into multiple active proteins by 3CL protease and PL protease. Therefore, inhibiting the activity of 3CL protease can effectively inhibit the replication of the virus. Different coronavirus 3CL proteases have a high degree of structural homology, so 3CL protease inhibitors have broad-spectrum anti-coronavirus activity.

[0004] In addition to coronaviruses, 3CL protease also plays an important role in the hydrolysis of polyproteins encoded by small RNA viruses. 3CL protease inhibitors can effectively inhibit the replication of small RNA viruses. Enterovirus 71 is a small RNA virus. It is one of the common viruses that cause hand, foot and mouth disease. It may also cause meningitis, brainstem encephalitis, myocarditis and other diseases. In recent years, enterovirus 71 has repeatedly broken out in infants and young children, and there is still a lack of effective therapeutic drugs in clinical practice.

[0005] Therefore, there is still a need for compounds that can inhibit RNA / picoRNA viruses including coronavirus / enterovirus 71. Summary of the invention

[0006] Based on the crystal structure of 3CL protease, the inventor rationally designed a class of cyano compounds, which can effectively inhibit the 3CL protease activity of coronaviruses and / or small RNA viruses, effectively inhibit the 3CL protease activity of various small RNA viruses including enterovirus 71 in vitro, effectively inhibit the replication of small RNA viruses at the cellular level, and can be used to prepare drugs for coronavirus and / or small RNA virus-induced diseases. The inventor completed the present disclosure on this basis.

[0007] The primary purpose of the present invention is to provide a cyano compound as shown in the general formula I, its racemate, enantiomer, diastereomer and pharmaceutically acceptable salt thereof.

[0008] The second object of the present invention is to provide a method for preparing the compound.

[0009] The third object of the present invention is to provide a pharmaceutical composition comprising the compound.

[0010] The fourth object of the present invention is the use of the compounds in preparing 3CL protease inhibitors.

[0011] The fifth object of the present invention is to use the compounds in the preparation of drugs for preventing or treating diseases induced by coronavirus and / or small RNA viruses.

[0012] In order to achieve the above purpose, the technical solution adopted by the present invention is:

[0013] In one aspect, the present invention provides a cyano compound as shown in Formula I, its racemate, enantiomer, diastereomer and pharmaceutically acceptable salts thereof.

[0014]

[0015] In another aspect, the present invention provides a method for preparing the compound of formula I.

[0016] The technical solution of the present invention has at least the following technical effects:

[0017] The compound of the present invention has 3CL protease inhibitory activity, can inhibit the hydrolysis of protein complexes expressed by coronavirus and small RNA viruses, and further inhibit virus replication and development, and can be used for the prevention and treatment of diseases caused by coronavirus or small RNA virus infection.

[0018] The present invention relates to a cyano compound represented by general formula I, a racemate, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof:

[0019]

[0020] in,

[0021] R 1 Selected from -COR 8 and -SO2 R 9 ;

[0022] R 2 With R 3 Each independently selected from H, D, C1-C 10 Alkyl, adamantyl and C3-C7 cycloalkyl, or, R 2 With R3 It forms a 3- to 8-membered carbon ring with the carbon atom it is connected to;

[0023] X is selected from O, S, S(═O)2 and S═O;

[0024] Y is absent or selected from O, S, S(=O)2 and S=O;

[0025] R 4 Selected from H, C1~C 10 Alkyl, C3~C8 cycloalkyl, C6~C 20 Aryl, C1~C 10 Alkyl substituted C6~C 20 Aryl, C1~C 10 Alkoxy substituted C6~C 20 Aryl and halogenated C6~C 20 Aryl;

[0026] R 5 Selected from H, C1~C 10 Alkyl and C3-C7 cycloalkyl;

[0027] Or, R 4 With R 5 Connected to each other to form a C2-C6 alkylene group, thereby connecting X and Y;

[0028] R 6 Selected from

[0029] R 7 Selected from H and D;

[0030] R 8 Selected from H, C1~C 10 Alkyl, C1~C 10 Alkoxy, C3-C7 cycloalkyl, halogenated C1-C 10 Alkyl, halogenated C3-C7 cycloalkyl, -NR 13 R 14 、C6~C 20 Aryl, halogenated C6~C 20 Aryl, C1~C 10 Alkyl substituted C6~C 20 Aryl, halogenated C1~C 10 Alkyl substituted C6~C 20 Aryl, 5- to 20-membered heteroaryl, and halogenated 5- to 20-membered heteroaryl;

[0031] R 9 Selected from C1~C 10 Alkyl, C3~C7 cycloalkyl, halogenated C1~C 10 Alkyl, halogenated C3-C7 cycloalkyl, -NR15 R 16 、C6~C 20 Aryl, halogenated C6~C 20 Aryl, C1~C 10 Alkyl substituted C6~C 20 Aryl, halogenated C1~C 10 Alkyl substituted C6~C 20 Aryl, 5- to 20-membered heteroaryl, and halogenated 5- to 20-membered heteroaryl;

[0032] R 13 and R 14 Each independently selected from H and C1~C 10 alkyl;

[0033] R 15 and R 16 Each independently selected from H and C1~C 10 alkyl.

[0034] In some embodiments, R 2 With R 3 Each independently selected from H, D, C1-C6 alkyl, adamantyl and C3-C7 cycloalkyl, or, R 2 With R 3 It forms a 3- to 8-membered carbon ring with the carbon atom it is connected to.

[0035] In some embodiments, R 2 With R 3 are each independently selected from H, isopropyl, tert-butyl, cyclopentyl and adamantyl, or, R 2 With R 3 Together with the carbon atom to which it is attached, it forms cyclopropyl and cyclopentyl.

[0036] In some embodiments, R 2 With R 3 one of them is selected from H, and the other is selected from isopropyl, tert-butyl, cyclopentyl and adamantyl, or, R 2 With R 3 Together with the carbon atom to which it is attached, it forms cyclopropyl and cyclopentyl.

[0037] In some embodiments, R 4 Selected from H, C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 Aryl, C1~C6 alkyl substituted C6~C 10 Aryl, C1~C6 alkoxy substituted C6~C 10 Aryl and halogenated C6~C 10 Aryl;

[0038] R 5is selected from H, C1-C6 alkyl and C3-C7 cycloalkyl;

[0039] Or, R 4 With R 5 They are connected to each other to form a C2-C6 alkylene group, thereby connecting X and Y.

[0040] In some embodiments, X is selected from O, S, S(=O)2 and S=O; Y is absent or selected from O, S and S=O; R 4 Selected from C1-C6 alkyl and C6-C 10 Aryl, R 5 Selected from H; or, R 4 With R 5 They are connected to each other to form a C2-C6 alkylene group, thereby connecting X and Y.

[0041] In some embodiments, R 4 With R 5 They are connected to each other to form CH2CH2 and CH2CH2CH2, thereby connecting X and Y.

[0042] In some embodiments, X and Y are each independently selected from O, S and S=O, R 4 With R 5 They are connected to each other to form CH2CH2 and CH2CH2CH2, thereby connecting X and Y.

[0043] In some embodiments, X and Y are each independently selected from O and S, and R 4 With R 5 They are connected to each other to form CH2CH2, thereby connecting X and Y.

[0044] In some embodiments, X and Y are both selected from S, or X and Y are both selected from O, R 4 With R 5 They are connected to each other to form CH2CH2, thereby connecting X and Y.

[0045] In some embodiments, X is selected from S, Y is absent, R 4 is selected from phenyl and isopropyl, R 5 Selected from H.

[0046] In some embodiments, R 6 Selected from

[0047] In some embodiments, R 7 Selected from H.

[0048] In some embodiments, R 8Selected from H, C1-C6 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl, halogenated C1-C6 alkyl, halogenated C3-C7 cycloalkyl, -NR 13 R 14 、C6~C 10 Aryl, halogenated C6~C 10 Aryl, C1~C6 alkyl substituted C6~C 10 C6~C6 substituted by aryl, halogenated C1~C6 alkyl 10 Aryl, 5- to 10-membered heteroaryl and halogenated 5- to 10-membered heteroaryl.

[0049] In some embodiments, R 8 Selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, -NR 13 R 14 , C3~C7 cycloalkyl, halogenated C3~C7 cycloalkyl, phenyl, halogenated phenyl, C1~C6 alkyl substituted phenyl, halogenated C1~C6 alkyl substituted phenyl and 5~6 membered heteroaryl.

[0050] In some embodiments, R 9 Selected from C1-C6 alkyl, C3-C7 cycloalkyl, halogenated C1-C6 alkyl, halogenated C3-C7 cycloalkyl, -NR 15 R 16 、C6~C 10 Aryl, halogenated C6~C 10 Aryl, C1~C6 alkyl substituted C6~C 10 C6~C6 substituted by aryl, halogenated C1~C6 alkyl 10 Aryl, 5- to 10-membered heteroaryl and halogenated 5- to 10-membered heteroaryl.

[0051] In some embodiments, R 9 The group consisting of C1-C6 alkyl, C3-C7 cycloalkyl, phenyl, C1-C6 alkyl-substituted phenyl and halogenated C1-C6 alkyl-substituted phenyl.

[0052] In some embodiments, R 13 and R 14 Each is independently selected from H and C1-C6 alkyl.

[0053] In some embodiments, R 15 and R 16 Each is independently selected from H and C1-C6 alkyl.

[0054] In some embodiments, R 8 Selected from CH3, CF3, CH2CF3, CF2CF3, methoxy, Cyclopropyl, Phenyl, and pyridin-3-yl.

[0055] In some embodiments, R 9 Selected from CH3, cyclopropyl, phenyl, p-methylphenyl and p-trifluoromethylphenyl.

[0056] In some embodiments, the cyano compound represented by Formula I is selected from the cyano compound represented by Formula IA:

[0057]

[0058] Among them, R 1 , R 2 , R 3 , R 4 , R 5 , X and Y are as defined above.

[0059] In some embodiments, the cyano compound represented by the general formula I is selected from the cyano compound represented by the general formula IB:

[0060]

[0061] Here, each substituent is as defined above.

[0062] In some embodiments, the cyano compound represented by the general formula I is selected from any one of the cyano compounds represented by the following general formulas:

[0063]

[0064] Among them, R 1 , R 2 , R 3 and R 6 As defined above.

[0065] In some embodiments, the compound represented by the general formula I of the present invention is selected from the following compounds:

[0066]

[0067]

[0068]

[0069]

[0070] The present invention provides a method for preparing the compound represented by general formula I, which is one of the following methods:

[0071] Method I:

[0072]

[0073] ia) obtaining a compound represented by formula IV by condensation reaction of the compound represented by formula II and the compound represented by formula III;

[0074] Preferably, the step ia) is: the compound represented by formula II is reacted with the compound represented by formula III in a solvent at a temperature of -20°C to 50°C by means of a condensing agent and a base for 0.1-12h to obtain the compound represented by formula IV;

[0075] Wherein, the solvent is one or a mixture of the following: tetrahydrofuran, dichloromethane, N,N-dimethylformamide, N,N-dimethylacetamide, ethyl acetate and 1,4-dioxane;

[0076] Optionally, the condensing agent is one or a mixture of the following: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, 2-hydroxypyridine-N-oxide, 1-propylphosphoric anhydride, 1H-benzotriazole-1-yloxytripyrrolidino hexafluorophosphate, N,N'-carbonyldiimidazole and O-benzotriazole-tetramethyluronium hexafluorophosphate;

[0077] Optionally, the base is N,N-diisopropylethylamine, triethylamine and N-methylmorpholine;

[0078] ib) dehydrating the compound represented by formula IV to obtain the compound represented by general formula I;

[0079] Preferably, the step ib) is: reacting the compound represented by formula IV with a dehydrating agent in an anhydrous solvent at a temperature of -20°C to 50°C for 1-24h to obtain a compound represented by general formula I;

[0080] Wherein, the anhydrous solvent is one or a mixture of the following: tetrahydrofuran, dichloromethane, toluene, 1,4-dioxane and pyridine;

[0081] The dehydrating agent is trifluoroacetic anhydride and methyl N-(triethylammoniumsulfonyl)carbamate; or

[0082] Method ii:

[0083]

[0084] iia) condensing the compound represented by formula V with the compound represented by formula III to obtain the compound represented by formula VI, wherein PG in the compound represented by formula V is a protecting group of the amino group;

[0085] Preferably, the step iia) is: the compound represented by formula V is reacted with the compound represented by formula III in a solvent at a temperature of -20°C to 50°C by means of a condensing agent and a base for 0.1-12 hours to obtain the compound represented by formula VI.

[0086] Wherein, the solvent is one or a mixture of the following: tetrahydrofuran, dichloromethane, N,N-dimethylformamide, N,N-dimethylacetamide, ethyl acetate and 1,4-dioxane,

[0087] The condensing agent is one or a mixture of the following: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, 2-hydroxypyridine-N-oxide, 1-propylphosphoric anhydride, 1H-benzotriazole-1-yloxytripyrrolidino hexafluorophosphate, N,N'-carbonyldiimidazole and O-benzotriazole-tetramethyluronium hexafluorophosphate;

[0088] The base is N,N-diisopropylethylamine, triethylamine and N-methylmorpholine;

[0089] The amino protecting group PG is tert-butyloxycarbonyl, benzyl and p-methoxybenzyl;

[0090] iib) deprotecting the compound represented by formula VI to obtain a compound represented by formula VII;

[0091] Preferably, the step iib) is: reacting the compound represented by formula VI with trifluoroacetic acid or an organic solution of hydrogen chloride or Pd / C / H2 at a temperature of -20°C to 50°C to obtain the compound represented by formula VII;

[0092] iic) the compound represented by formula VII is subjected to aminoacylation, sulfonylation or condensation reaction to obtain the compound represented by formula IV;

[0093] Preferably, the step iic) is:

[0094] At a temperature of -20°C to 50°C, the compound represented by formula VII is subjected to aminoacylation reaction with an acid chloride or an acid anhydride under the condition of adding a base to obtain a compound represented by formula IV; or,

[0095] At a temperature of -20°C to 50°C, the compound represented by formula VII is subjected to a sulfonylation reaction with sulfonyl chloride or sulfonic anhydride under alkaline conditions to obtain a compound represented by formula IV; or,

[0096] At a temperature of -20°C to 50°C, the compound represented by formula VII and a carboxyl compound are subjected to a condensation reaction in the presence of a condensing agent and a base to obtain a compound represented by formula IV;

[0097] Optionally, the base is N,N-diisopropylethylamine, triethylamine and N-methylmorpholine;

[0098] Optionally, the condensing agent is one or a mixture of the following: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, 2-hydroxypyridine-N-oxide, 1-propylphosphoric anhydride, 1H-benzotriazole-1-yloxytripyrrolidino hexafluorophosphate, N,N'-carbonyldiimidazole and O-benzotriazole-tetramethyluronium hexafluorophosphate,

[0099] iid) the compound represented by formula IV is dehydrated to obtain the compound represented by general formula I;

[0100] Preferably, the step iid) is: the compound represented by formula IV is reacted with a dehydrating agent in an anhydrous solvent at a temperature of -20°C to 50°C for 1-24h to obtain a compound represented by general formula I;

[0101] Wherein, the anhydrous solvent is one or a mixture of the following: tetrahydrofuran, dichloromethane, toluene, 1,4-dioxane and pyridine;

[0102] Optionally, the dehydrating agent is trifluoroacetic anhydride and methyl N-(triethylammoniumsulfonyl)carbamate,

[0103] Here, each substituent is as defined above.

[0104] Another aspect of the present invention provides a pharmaceutical composition comprising one or more of a cyano compound selected from the group consisting of a racemate, an enantiomer, a diastereomer, and a pharmaceutically acceptable salt thereof of the general formula I. The pharmaceutical composition may further comprise one or more pharmaceutically acceptable excipients, diluents, carriers, excipients, or adjuvants.

[0105] On the other hand, the present invention also provides a pharmaceutical composition, which comprises a cyano compound selected from the general formula I, or a racemate, enantiomer, diastereomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient; optionally, the pharmaceutical composition further comprises ritonavir or a pharmaceutically acceptable salt thereof.

[0106] Another aspect of the present invention provides a pharmaceutical combination comprising a cyano compound selected from the group consisting of general formula I, racemates, enantiomers, diastereomers or pharmaceutically acceptable salts thereof, and ritonavir or a pharmaceutically acceptable salt thereof.

[0107] Another aspect of the present invention provides a pharmaceutical composition comprising a cyano compound selected from the group consisting of general formula I or a pharmaceutically acceptable salt thereof, ritonavir or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0108] Experiments have shown that the compounds of the present invention have the activity of inhibiting coronavirus 3CL protease and small RNA virus 3CL protease.

[0109] Therefore, in another aspect, the present invention provides a coronavirus 3CL protease inhibitor and / or a picornavirus 3CL protease inhibitor, which comprises one or more selected from the cyano compound of general formula I, its racemate, enantiomer and diastereomer, and their pharmaceutically acceptable salts, or the above-mentioned pharmaceutical composition.

[0110] The present invention also provides the use of the above-mentioned cyano compound, its racemate, enantiomer, diastereomer, pharmaceutically acceptable salt thereof, or a mixture thereof, or the above-mentioned pharmaceutical composition in the preparation of a drug, wherein the drug is selected from a drug for inhibiting the activity of coronavirus 3CL protease, a drug for preventing and / or treating coronavirus infection, a drug for inhibiting the 3CL protease activity of a small RNA virus, and a drug for preventing and / or treating a small RNA virus infection.

[0111] The present invention also provides a method for inhibiting 3CL protease, which comprises administering to a subject in need of treatment one or more of a cyano compound selected from the group consisting of general formula I of the present invention, its racemates, enantiomers and diastereomers, and pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to the present invention.

[0112] The present invention also provides a method for preventing and / or treating a disease or condition, comprising administering to a subject in need of treatment a cyano compound selected from the group consisting of general formula I of the present invention, one or more of its racemates, enantiomers and diastereomers, and pharmaceutically acceptable salts thereof, or a pharmaceutical composition according to the present invention, wherein the disease or condition is a 3CL protease-mediated disease or condition, in particular a disease or condition associated with coronavirus infection and / or picornavirus infection.

[0113] The present invention also provides the use of the cyano compound represented by the above-mentioned general formula I, one or more of its racemates, enantiomers and diastereomers, and their pharmaceutically acceptable salts, or a pharmaceutical composition thereof in the preparation of a drug for preventing or treating related diseases caused by coronavirus and / or small RNA virus infection.

[0114] The present invention also provides a method for preventing or treating related diseases caused by coronavirus and / or picornavirus infection, which comprises administering to a patient a therapeutically effective dose of a pharmaceutical preparation comprising a cyano compound represented by general formula I of the present invention, its racemate, enantiomer and diastereoisomer, and one or more of their pharmaceutically acceptable salts.

[0115] In some embodiments, the coronavirus is selected from SARS-CoV, MERS-CoV, H229E-CoV, HKU1-CoV, NL63-CoV, OC43-CoV or SARS-CoV-2.

[0116] In some embodiments, the related disease caused by the coronavirus infection is selected from respiratory tract infection, pneumonia or its complications.

[0117] Definitions and explanations of terms

[0118] "C1~C 10 The term "alkyl" refers to a straight or branched saturated hydrocarbon group having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms. Specific examples of the alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylbutyl ...butyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylbutyl, 1,2-dimethylbutyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylbutyl, 1,2-dimethylbutyl, 1,2-dimethylpropyl, The term "C1-C6 alkyl" refers to a linear or branched alkyl group containing 1 to 6 carbon atoms, including but not limited to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, hexyl, etc.

[0119] "Alkylene" may be understood to mean a straight-chain or branched saturated divalent hydrocarbon group. "C2-C6 alkylene" may be understood to mean a straight-chain or branched saturated divalent hydrocarbon group having 2-6 carbon atoms, including but not limited to CH2CH2, CH2CH2CH2, CH2CH2CH2CH2, CH2CH2CH2CH2, CH2CH2CH2CH2CH2 or CH2CH2CH2CH2CH2CH2, etc.

[0120] "C3-C8 cycloalkyl" means a cyclic alkyl group containing 3-8 ring carbon atoms. "C3-C7 cycloalkyl" means a cyclic alkyl group containing 3-7 ring carbon atoms. The cycloalkyl group disclosed herein includes, but is not limited to, cyclopropyl, methylcyclopropyl, ethylcyclopropyl, dimethylcyclopropyl, cyclobutyl, methylcyclobutyl, ethylcyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0121] "C1~C 10 "Alkoxy" means a linear, branched or cyclic alkoxy group containing 1 to 10 carbon atoms. "C1-C6 alkoxy" means a linear, branched or cyclic alkoxy group containing 1 to 6 carbon atoms. The alkoxy group disclosed herein includes but is not limited to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentyloxy, isopentyloxy, cyclopentyloxy, hexyloxy, cyclohexyloxy and the like.

[0122] "Aryl" refers to an all-carbon monocyclic or fused polycyclic aromatic ring group having a conjugated π electron system. The aryl group may have 6-20 carbon atoms, 6-14 carbon atoms, or 6-12 carbon atoms. 20 The term "aryl" is understood to mean an aromatic radical having 6 to 20 carbon atoms. In particular, a ring having 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring having 9 carbon atoms ("C9 aryl"), such as indanyl or indenyl; or a ring having 10 carbon atoms ("C 10 or a ring having 13 carbon atoms ("C 13 or a ring having 14 carbon atoms ("C 14 "C6~C 10 "Aryl" is understood to mean an aromatic radical having 6 to 10 carbon atoms. In particular, a ring having 6 carbon atoms ("C6 aryl"), such as phenyl; or a ring having 9 carbon atoms ("C9 aryl"), such as indanyl or indenyl; or a ring having 10 carbon atoms ("C 10 "aryl"), for example tetrahydronaphthyl, dihydronaphthyl or naphthyl.

[0123] “Heteroaryl” is a cyclic aromatic radical containing 5 to 20 ring atoms, one or more of which are heteroatoms selected from N, O or S, and the remaining ring atoms are carbon. “5-20 membered heteroaryl” is understood as a heteroaryl radical having 5 to 20 ring atoms, in particular 5 or 6 or 9 or 10 or 13 or 14 ring atoms, and which contains 1 to 7 heteroatoms independently selected from N, O and S. “5-10 membered heteroaryl” is understood as a heteroaryl radical having 5 to 10 ring atoms, in particular 5 or 6 or 9 or 10 ring atoms, and which contains 1 to 5 heteroatoms independently selected from N, O and S. “5-6 membered heteroaryl” is understood as a heteroaryl radical having 5 or 6 ring atoms and which contains 1 to 3 heteroatoms independently selected from N, O and S. The heteroaryl group of the present invention can be selected from thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl or thiadiazolyl and their benzo derivatives, such as benzofuranyl, benzothienyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzotriazolyl, indazolyl, indolyl or isoindolyl, or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl and their benzo derivatives, such as quinolyl, quinazolinyl or isoquinolyl, or azinyl, indolizinyl, purinyl and their benzo derivatives, or cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl or phenoxazinyl, or the like.

[0124] "Halogen" is selected from fluorine, chlorine, bromine and iodine.

[0125] "Halogenated" includes monohalogenated, polyhalogenated or perhalogenated, that is, one, more than one or all hydrogen atoms are replaced by halogen.

[0126] "Substituted" means that one or more hydrogen atoms on a group are replaced by one or more substituents.

[0127] The term "optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes both the occurrence of said event or circumstance and the non-occurrence of said event or circumstance.

[0128] "Therapeutically effective amount" means an amount of a compound of the present invention that (i) treats a particular disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a particular disease, condition, or disorder, or (iii) delays the onset of one or more symptoms of a particular disease, condition, or disorder as described herein. The amount of a compound of the present invention that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art based on their own knowledge and this disclosure.

[0129] "Pharmaceutically acceptable salt" refers to a salt of a pharmaceutically acceptable acid or base, including a salt formed between a compound and an inorganic acid or an organic acid, and a salt formed between a compound and an inorganic base or an organic base.

[0130] The term "drug combination" refers to a combination comprising two or more active ingredients or pharmaceutically acceptable salts thereof. In some embodiments of the present invention, the active ingredients or pharmaceutically acceptable salts thereof in the drug combination may be administered simultaneously, and in some embodiments of the present invention, the active ingredients or pharmaceutically acceptable salts thereof in the drug combination may also be administered separately or sequentially.

[0131] "Pharmaceutical composition" refers to a mixture of one or more compounds of the present invention or their salts and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present invention to an organism.

[0132] "Pharmaceutically acceptable excipients" refer to those excipients that have no significant irritation to the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0133] Figure 1 This is a graph showing the inhibition rate-concentration of compound 2 against the in vitro activity of the WIV04 strain of SARS-CoV-2.

[0134] Figure 2 This is a graph showing the inhibition rate-concentration of compound 2 against the in vitro activity of the B.1.351 strain of SARS-CoV-2.

[0135] Figure 3 Graph showing the inhibitory effect of Compound 2 on virus titer in mouse lungs 2 days after infection (Figure A) and 4 days after infection (Figure B) in Example 26.

[0136] Figure 4 This is a graph showing the weight changes of mice in Example 26.

[0137] Figure 5 This is a graph showing the inhibitory effect of compound 2 on the virus titer in the mouse brain 4 days after infection in Example 26. DETAILED DESCRIPTION

[0138] The present disclosure is further described below by way of examples. In the following examples, the starting materials are commercially available or can be prepared by methods described in literature / organic synthesis methods known in the art.

[0139] Example 1

[0140] Preparation of compound 1-1:

[0141]

[0142] Step 1: The starting material SMA (2.74 g, 11.85 mmol), 35 ml of dichloromethane and 35 ml of DMF were added to a reaction flask, cooled to 0°C, and the starting material SMB (3.56 g, 11.86 mmol), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP, 6.29 g, 14.22 mmol) and N-methylmorpholine (NMM, 3.91 ml, 35.56 mmol) were added in sequence, and the temperature was raised to room temperature for reaction for 10 h. After the reaction was completed, an appropriate amount of dichloromethane was added, and the organic phase was washed with 1N hydrochloric acid aqueous solution and saturated brine in sequence. After washing, the organic phase was dried over anhydrous sodium sulfate, and the organic phase was concentrated to dryness. 3.71 g of INT-1 was obtained by column chromatography; ESI-MS: 433.2 m / z [M+H] + ; 1 H NMR (400 MHz, DMSO-d6): δ H :6.75(d,J=9.2Hz,1H),4.38(t,J=8.2Hz,1H),4.25(d,J=10.9Hz,1H),4.11(d,J=9.3Hz,1H),3.93(t,J=9.3Hz,1H),3 .62(s,3H),3.40-3.31(m,4H),2.70(dd,J=13.1,7.9Hz,1H),2.37(dd,J=13.2,8.4Hz,1H),1.37(s,9H),0.94(s,9H).

[0143] Step 2: INT-1 (3.71 g, 8.58 mmol), 37 ml of THF, 37 ml of purified water and lithium hydroxide monohydrate (0.72 g, 17.16 mmol) were added to a reaction flask and reacted at room temperature for 2 h. After the reaction, the pH was adjusted to 4 with concentrated hydrochloric acid and filtered to obtain 3.4 g of compound 1-1; ESI-MS: 419.2 m / z [M+H] + ; 1 H NMR (400 MHz, DMSO-d6): δ H :12.68(s,1H),6.71(d,J=9.4Hz,1H),4.38-4.19(m,2H),4.11(d,J=9.4Hz,1H),3.88(d,J=10.9Hz,1H), 3.41-3.29(m,4H),2.69(dd,J=13.1,7.9Hz,1H),2.34(dd,J=13.2,8.9Hz,1H),1.38(s,9H),0.94(s,9H).

[0144] Preparation of compound 1-2:

[0145]

[0146] Add ammonia-methanol solution (700ml, 7mol / L) and starting material SMD (100g, 0.349mol) into the reaction flask, stir to dissolve, keep warm at 25±5℃, and react for 36h. After the reaction, concentrate the reaction solution until the remaining reaction solution is about 250ml, add 300ml of isopropanol and continue to concentrate under reduced pressure until the remaining reaction solution is about 250ml (repeat three times), replace with nitrogen, cool to 10±5℃, add 500ml of hydrogen chloride-isopropanol solution (4mol / L) into the reactor, after the addition is completed, heat to 25±5℃, keep warm at 25±5℃ and react for 9h. After the reaction was completed, the reaction solution was concentrated under reduced pressure to a residual reaction solution volume of about 250 ml, 300 ml of isopropanol was added and the reaction solution was further concentrated under reduced pressure to a residual reaction solution volume of about 250 ml (repeated twice), 100 ml of isopropanol was added, stirred for 30±5 min, filtered, and the filter cake was rinsed with 50 ml of isopropanol to obtain a wet product; vacuum dried at 45±5° C. to obtain 66.7 g of compound 1-2, with a yield of 92%; 1 H NMR (400 MHz, DMSO-d6): δ H :8.45(d,J=5.1Hz,3H),8.25-8.04(m,1H),7.95(s,1H),7.67-7.49(m,1H),3.85-3.80(m,1H),3.19-3.13( m,2H),2.59-2.51(m,1H),2.32-2.27(m,1H),2.05-1.98(m,1H),1.82-1.66(m,2H); ESI-MS:172.1m / z[M+H] + .

[0147] Preparation of compound 1:

[0148]

[0149] Compound 1-1 (419 mg, 1 mmol) was placed in a two-necked bottle, 5 mL of dichloromethane was added under nitrogen protection, and then 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (400 mg, 1.1 mmol) was added and stirred at room temperature for 1 h. Compound 1-2 (1 mmol) was dissolved in 1 mL of dichloromethane and added to the above system, and then N,N-diisopropylethylamine (0.5 mL, 1 mmol) was added under an ice-water bath, the ice-water bath was removed, and the system was stirred at room temperature overnight. After post-treatment, 50 mL of dichloromethane was added and washed three times with 1M hydrochloric acid aqueous solution, three times with saturated sodium bicarbonate aqueous solution, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and dried to obtain compound 1-3 (white solid, 469 mg, yield 82%). ESI-MS: m / z 572.3 [M+H] + .

[0150] Compound 1-3 (114 mg, 0.2 mmol) and Burgess reagent (1.5 eq) were added to a two-necked bottle, nitrogen was charged and discharged three times, and then dichloromethane dried over molecular sieves was added. The mixture was stirred at room temperature overnight. Thin layer chromatography showed that the raw materials were basically reacted. After treatment, column chromatography gave compound 1 (white solid, 52 mg, yield 47%), ESI-MS: 554.3 m / z [M+H] + .

[0151] Example 2

[0152]

[0153] Compound 1-3 (572 mg, 1 mmol) was dissolved in 3 mL 4M hydrogen chloride / 1,4-dioxane solution, or dissolved in 2 mL dichloromethane and then 2 mL trifluoroacetic acid was added dropwise, stirred at ambient temperature, and the solvent was fully dried after thin layer chromatography showed that the raw material was basically reacted. The crude product was dissolved in 2 mL dichloromethane, nitrogen protection, triethylamine (3 mmol) was added and the system was placed in an ice water bath, trifluoroacetic anhydride (1.2 mmol) was added dropwise, and after thin layer chromatography showed that the raw material was basically reacted, 50 mL of dichloromethane was added and washed three times with 1M hydrochloric acid aqueous solution, washed three times with saturated sodium bicarbonate aqueous solution, washed the organic phase with saturated brine, dried over anhydrous sodium sulfate, and passed through a column to obtain compound 2-1 (white solid, 265 mg, yield 46%). ESI-MS: m / z 568.3 [M+H] + .

[0154] Compound 2-1 (113 mg, 0.2 mmol) and Burgess reagent (1.5 eq) were added to a two-necked bottle, nitrogen was filled and discharged three times, and then dichloromethane dried over molecular sieves was added. The mixture was stirred at room temperature overnight. Thin layer chromatography showed that the raw materials were basically reacted. After post-treatment, column chromatography gave compound 2 (white solid, 41 mg, yield 47%). 1 H NMR (400MHz, DMSO-d6) δ9.46(d,J=8.7Hz,1H),9.05(d,J=8.6Hz,1H),7.67(s,1H),4.97(ddd,J=11.0,8.5,5.0 Hz,1H),4.53(d,J=8.7Hz,1H),4.34(dd,J=9.9,7.1Hz,1H),4.26-4.14(m,1H),3.92(d,J=10.9Hz,1H),3.50-3. 34(m,4H),3.22-3.11(m,1H),3.06(td,J=9.3,7.1Hz,1H),2.68-2.58(m,1H),2.50-2.43(m,1H),2.31(dd,J=1 3.0,10.0Hz,1H),2.23-2.07(m,2H),1.71(tdd,J=14.9,10.3,7.4Hz,2H),0.99(s,9H).ESI-MS:550.3m / z[M+H] + .

[0155] Example 3

[0156]

[0157] The same method as in Example 2 was followed, except that acetic anhydride was used instead of trifluoroacetic anhydride to obtain compound 3 (white solid, 45 mg, yield 45%), ESI-MS: 496.3 m / z [M+H] + .

[0158] Example 4

[0159]

[0160] The same method as in Example 2 was followed, except that cyclopropanecarboxylic anhydride was used instead of trifluoroacetic anhydride to obtain compound 4 (white solid, 32 mg, yield 31%), ESI-MS: 522.3 m / z [M+H] + .

[0161] Example 5

[0162]

[0163] The same method as in Example 1 was used, except that 5-1 was used instead of 1-1 to obtain compound 5 (white solid, 22 mg, yield 20%). 1 H NMR (400MHz, DMSO-d6) δ9.03(d,J=8.4Hz,1H),7.67(s,1H),7.41(dd,J=9.1,2.6Hz,1H),4.96(ddd,J=10.6,8.4,5 .4Hz,1H),4.58-4.50(m,1H),4.34(dd,J=9.8,7.2Hz,1H),4.26-4.21(m,1H),3.89(d,J=11.0Hz,1H),3.45-3.33( m,4H),3.22-3.03(m,2H),2.64-2.57(m,1H),2.45(ddd,J=10.1,8.5,4.5Hz,1H),2.31(dd,J=12.9,9.8Hz,1H),2. 20-2.10(m,2H),1.84-1.67(m,2H),1.39-1.31(m,2H),1.24(t,J=9.5Hz,2H),0.97(s,9H).ESI-MS:540.2m / z[M+H] + .

[0164] Example 6

[0165]

[0166] The same method as in Example 1 was followed, except that 6-1 was used instead of 1-1 to obtain compound 6 (white solid, 38 mg, yield 37%), ESI-MS: 512.2 m / z [M+H] + .

[0167] Example 7

[0168]

[0169] The same method as in Example 1 was followed, except that 7-1 was used instead of 1-1 to obtain compound 7 (white solid, 49 mg, yield 44%), ESI-MS: 553.3 m / z [M+H] + .

[0170] Example 8

[0171]

[0172] The same method as in Example 2 was followed, except that benzoic anhydride was used instead of trifluoroacetic anhydride to obtain compound 8 (white solid, 44 mg, yield 39%), ESI-MS: 558.3 ​​m / z [M+H] + .

[0173] Example 9

[0174]

[0175] The same method as in Example 2 was followed, except that 3,5-bis(trifluoromethyl)benzoyl chloride was used instead of trifluoroacetic anhydride to obtain compound 9 (white solid, 39 mg, yield 28%), ESI-MS: 694.2 m / z [M+H] + .

[0176] Example 10

[0177]

[0178] The same method as in Example 2 was followed, except that 3,5-dimethylbenzoyl chloride was used instead of trifluoroacetic anhydride to obtain compound 10 (white solid, 31 mg, yield 26%), ESI-MS: 586.2 m / z [M+H] + .

[0179] Embodiment 11

[0180]

[0181] The same method as in Example 2 was followed, except that 3,3,3-trifluoropropionic anhydride was used instead of trifluoroacetic anhydride to obtain compound 11 (white solid, 28 mg, yield 25%), ESI-MS: 564.2 m / z [M+H] + .

[0182] Example 12

[0183]

[0184] The same method as in Example 2 was followed, except that 3-pyridinecarbonyl chloride was used instead of trifluoroacetic anhydride to obtain compound 12 (white solid, 39 mg, yield 35%), ESI-MS: 559.2 m / z [M+H] + .

[0185] Example 13

[0186]

[0187] The same method as in Example 2 was followed, except that pentafluoropropionyl chloride was used instead of trifluoroacetic anhydride to obtain compound 13 (white solid, 41 mg, yield 34%), ESI-MS: 600.2 m / z [M+H] + .

[0188] Embodiment 14

[0189]

[0190] The same method as in Example 1 was followed, except that 14-1 was used instead of 1-1 to obtain compound 14 (white solid, 32 mg, yield 29%), ESI-MS: 550.2 m / z [M+H] + .

[0191] Embodiment 15

[0192]

[0193] The same method as in Example 2 was followed, except that trifluoroacetic anhydride was replaced with methylsulfonic anhydride to obtain compound 15 (white solid, 38 mg, yield 36%). 1 H NMR (400MHz, Methanol-d4) δ5.06 (dd, J=11.5, 4.5Hz, 1H), 4.46 (dd, J=10.3, 7.1Hz, 1H), 4.27 (dd,J=11.0,1.6Hz,1H),4.02-3.89(m,2H),3.45(qt,J=8.6,4.7Hz,4H),3.30-3.23(m,1H),2. 92(s,3H),2.78(tdd,J=10.3,8.5,4.0Hz,1H),2.68(ddd,J=13.0,7.2,1.6Hz,1H),2.51(dd,J= 13.0,10.3Hz,1H),2.45-2.27(m,2H),1.94-1.77(m,2H),1.05(s,9H).ESI-MS:532.2m / z[M+H] + .

[0194] Example 16

[0195]

[0196] The same method as in Example 2 was followed, except that cyclopropanesulfonyl chloride was used instead of trifluoroacetic anhydride to obtain compound 16 (white solid, 29 mg, yield 26%). 1H NMR(400MHz, Methanol-d4)δ5.06(dd,J=11.5,4.5Hz,1H),4.44(dd,J=10.3,7.0Hz,1H),4.28(dd,J=11.0,1.6Hz,1H), 4.00-3.94(m,2H),3.52-3.38(m,4H),3.31-3.21(m,1H),2.79(tdd,J=10.4,8.5,4.1Hz,1H),2.72-2.65(m,1H),2.57( ddd,J=7.9,6.2,3.9Hz,1H),2.51(dd,J=13.0,10.4Hz,1H),2.43-2.29(m,2H),1.92-1.74(m,2H),1.34-1.29(m,1H),1 .14(qt,J=6.4,3.8Hz,1H),1.06(s,9H),1.01(ddt,J=7.9,5.8,2.7Hz,2H),0.97-0.87(m,1H).ESI-MS:558.2m / z[M+H] + .

[0197] Embodiment 17

[0198]

[0199] The same method as in Example 2 was followed, except that benzenesulfonyl chloride was used instead of trifluoroacetic anhydride to obtain compound 17 (white solid, 35 mg, yield 29%), ESI-MS: 594.2 m / z [M+H] + .

[0200] Embodiment 18

[0201]

[0202] The same method as in Example 1 was followed, except that 18-1 was used instead of 1-1 to obtain compound 18 (white solid, 44 mg, yield 42%), ESI-MS: 518.2 m / z [M+H] + .

[0203] Embodiment 19

[0204]

[0205] The same method as in Example 1 was followed, except that 19-1 was used instead of 1-1 to obtain compound 19 (white solid, 41 mg, yield 36%), ESI-MS: 568.2 m / z [M+H] + .

[0206] Embodiment 20

[0207]

[0208] The same method as in Example 1 was followed, except that 20-1 was used instead of 1-1 to obtain compound 20 (white solid, 45 mg, yield 35%), ESI-MS: 648.2 m / z [M+H] + .

[0209] Embodiment 21

[0210]

[0211] The same method as in Example 1 was followed, except that 21-1 was used instead of 1-1 to obtain compound 21 (white solid, 34 mg, yield 31%), ESI-MS: 640.2 m / z [M+H] + .

[0212] Embodiment 22

[0213]

[0214] The same method as in Example 1 was followed, except that 22-1 was used instead of 1-1, and 22--1 was used instead of 1-2 to obtain compound 22 (white solid, 22 mg, yield 18%), ESI-MS: 614.2 m / z [M+H] + .

[0215] Embodiment 23

[0216]

[0217] Compound 23-1 (497 mg, 1 mmol) was placed in a two-necked bottle, 5 mL of dichloromethane was added under nitrogen protection, and then 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (400 mg, 1.1 mmol) was added and stirred at room temperature for 1 h. Compound 1-2 (or its corresponding salt, 1 mmol) was dissolved in 1 mL of dichloromethane and added to the above system, and then N,N-diisopropylethylamine (0.5 mL, 1 mmol) was added under an ice-water bath, the ice-water bath was removed, and the system was stirred at room temperature overnight. After post-treatment, 50 mL of dichloromethane was added and washed three times with 1M hydrochloric acid aqueous solution, three times with saturated sodium bicarbonate aqueous solution, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered and dried to obtain compound 23-2 (white solid, 421 mg, yield 65%). ESI-MS: m / z 650.3 [M+H] + .

[0218] Compound 23-2 (325 mg, 0.5 mmol) was dissolved in 1.5 mL 4M hydrogen chloride / 1,4-dioxane solution, or dissolved in 1 mL dichloromethane and then 1 mL trifluoroacetic acid was added dropwise, stirred at ambient temperature, and the solvent was fully dried after thin layer chromatography showed that the raw material was basically reacted. The obtained crude product was dissolved in 2 mL dichloromethane, nitrogen protection, and triethylamine (1.5 mmol) was added and the system was placed in an ice water bath, and trifluoroacetic anhydride (0.6 mmol) was added dropwise. After the thin layer chromatography showed that the raw material was basically reacted, 25 mL of dichloromethane was added and washed three times with 1M hydrochloric acid aqueous solution, washed three times with saturated sodium bicarbonate aqueous solution, and washed the organic phase with saturated brine, dried over anhydrous sodium sulfate, and passed through a column to obtain compound 23-3 (white solid, 167 mg, yield 52%). ESI-MS: m / z 646.3 [M+H] + .

[0219] Compound 23-3 (130 mg, 0.2 mmol) and Burgess reagent (1.5 eq) were added to a two-necked bottle, nitrogen was filled and discharged three times, and then dichloromethane dried over molecular sieves was added. The mixture was stirred at room temperature overnight. Thin layer chromatography showed that the raw materials were basically reacted. After treatment, column chromatography gave compound 23 (white solid, 37 mg, yield 29%), ESI-MS: 628.2 m / z [M+H] + .

[0220] Example 24: Compounds inhibiting SARS-CoV-2 3CLpro activity test

[0221] Fluorescence resonance energy transfer method was used to evaluate the activity of compounds against SARS-CoV-2 3CL pro The volume of the entire enzymatic reaction system is 120 μL, the final concentration of the protease is 30 nM, and the final concentration of the substrate is 20 μM. The buffer of the reaction system includes 50 mM Tris pH 7.3 and 1 mM EDTA. SARS-CoV-23CL was added to the 96-well plate. pro Protease and compounds of different concentrations were incubated at 30°C for 10 minutes, and the substrate was added and quickly placed in a microplate reader for reading. The excitation light and emission light were 320nM and 405nM, respectively. The test time was 3.5 minutes, and the fluorescence value was read every 35 seconds. The final result was the reaction rate fitted with the readings of the first 2 minutes, and compared with the control group (DMSO) to calculate the inhibition rate. The IC was fitted using the software GraphPad Prism 8. 50 Values ​​and inhibition rate curves.

[0222] The experimental results are shown in Table 1. The results show that the compounds of the present invention have an effective effect on SARS-CoV-2 3CL pro Has a strong inhibitory effect. IC50 The range of values ​​is: A represents <0.1 μM, B represents 0.1-1 μM, and C represents 1-10 μM.

[0223] Table 1: Compounds 1-23 against SARS-CoV-2 3CL pro The inhibitory effect

[0224]

[0225]

[0226]

[0227]

[0228]

[0229] Example 24-2: Test of the inhibitory activity of compound 2 on the mutant 3CL protease of SARS-CoV-2 Omicron strain

[0230] Experimental principle: The method of fluorescence resonance energy transfer (FRET) produced by the reaction between enzyme and substrate was used to study the inhibitory effect of the compound of the present invention on the activity of mutant 3CL protease (P132H) of Omicron strain.

[0231] The experimental materials are shown in the following table:

[0232]

[0233] Experimental instruments and equipment:

[0234] Instrument Name brand model Echo Nano Upgrade Sonic Wave Shift System Labcyte Echo 650 Flexstation 3 Microplate Reader MolecMar Devices FLEX3 Centrifuge Eppendorf 5810

[0235] Experimental steps:

[0236] Prepare a reaction buffer containing 20mM Tris-HCl, 1mM EDTA, 0.01% BSA, 1mM DTT and 100mM NaCl. Use the Echo pipetting system to dilute the test compound to different concentrations in dimethyl sulfoxide (DMSO) and transfer it to a 384-well plate. Dilute the mutant 3CL protease with reaction buffer and add it to the 384-well plate at 10μL / well, centrifuge at 1000rpm for 1min, and then incubate at room temperature for 30 minutes. Then add 10μL / well of substrate and centrifuge at 1000rpm for 30s to start the enzyme reaction. In the reaction system, the final concentration of the enzyme is 50nM, the final concentration of the substrate is 20μM, and the concentration range of the compound is 10000nM to 0.51nM. Then, the Kinetic Reduction Vmax mode was selected on the Flexstation 3 microplate reader, and the fluorescence value at a wavelength of 490 nm was read continuously every 75 seconds for a total of 35 times to obtain the reaction rate value (V), calculate the inhibition rate, and use XLfit software for four-parameter fitting to obtain the half-maximal inhibition concentration (IC 50 ). The inhibition rate is calculated as follows:

[0237] Inhibition rate = (V max -V compound ) / (V max -V min )*100%

[0238] Among them, V max is the reaction rate value of the well containing only enzyme and substrate, V min is the reaction rate value of the well containing only substrate, V Compound is the reaction rate value for the wells containing the test compound, enzyme and substrate.

[0239] Experimental results: Compound 2 still maintained significant inhibitory activity against the 3CL protease with P132H mutation in the SARS-CoV-2 Omicron strain (IC 50 is 0.022±0.00090μM).

[0240] Table 2: Inhibitory effect of compound 2 on 3CL protease activity of SARS-CoV-2 Omicron strain

[0241] 3CL protease <![CDATA[Compound 2 IC 50 (μM) (n = 3*)]]> SARS-CoV-2 (Omicron strain) 0.022±0.00090

[0242] *Indicates three independent repeated experiments.

[0243] Example 24-3: Test of the inhibitory activity of compound 2 on coronavirus 3CL protease from different sources

[0244] Experimental purpose: To study the inhibitory effect of compound 2 on the 3CL protease activity of six other coronaviruses that can infect humans, namely SARS-CoV, MERS-CoV, OC43-CoV, H229E-CoV, NL63-CoV and HKU1-CoV.

[0245] Experimental Materials:

[0246] 3CL protease: Recombinant full-length coronavirus 3CL protease was prepared according to the coronavirus genome sequence. The GenBank numbers of the SARS-CoV, MERS-CoV, H229E-CoV, HKU1-CoV, NL63-CoV and OC43-CoV genomes used were AAP13442.1, MT387202.1, AF304460.1, AY597011.2, AY567487.2 and AY903459.1, respectively. The DNA sequences required for the expression of the six coronavirus 3CL protease proteins were purchased from Nanjing GenScript Biotechnology Co., Ltd.

[0247] 3CL protease substrate was purchased from Nanjing GenScript Biotechnology Co., Ltd.

[0248] Chymotrypsin substrate was purchased from Gill Biochemical Co., Ltd.

[0249] Other reagents are shown in the following table:

[0250] Reagents and Materials brand Part Number Chymotrypsin from bovine pancreas Sigma C4129 Tris Sigma BCBX3837 EDTA Sigma 0001434776

[0251] Experimental steps:

[0252] Prepare reaction buffer (containing 50mM Tris and 1mM EDTA). The test compound was dissolved into a 100mM stock solution with DMSO, and further diluted 2-fold with reaction buffer for a total of 11 concentrations. 3CL protease and different concentrations of compounds were added to a 96-well plate, incubated at room temperature for 10 minutes, substrate was added and quickly placed in a microplate reader for reading. The volume of the entire enzymatic reaction system was 120μL, and the final concentrations of SARS-CoV, MERS-CoV, H229E-CoV, HKU1-CoV, NL63-CoV and OC43-CoV proteases were 30nM, 80nM, 30nM, 20nM, 30nM and 10nM, respectively, and the final concentration of substrate was 10μM. The excitation light and emission light wavelengths were 340nm and 490nm, respectively, when reading. The test time was 10 minutes, and the fluorescence value was read every 1 minute. The final result was the reading value of the first 5 minutes to fit the reaction rate and calculate the inhibition rate. The calculation formula was: inhibition rate = 1-(test group reaction rate / control group reaction rate).

[0253] Experimental results: The results are shown in Table 3. Compound 2 showed a good inhibitory effect on 3CL proteases from six other coronaviruses, suggesting that compound 2 may have a broad-spectrum anti-coronavirus activity.

[0254] Table 3: Inhibitory effect of compound 2 on 3CL proteases from other coronaviruses

[0255] Source of 3CL protease <![CDATA[Compound 2 IC 50 (μM)]]> HKU1-CoV 0.0049 OC43-CoV 0.010 SARS-CoV-1 0.024 MERS-CoV 0.060 H229E-CoV 0.13 NL63-CoV 0.85

[0256] Example 25-1: Inhibitory effect of compound 2 on SARS-CoV-2 WIV04 and B.1.351 strains at the cellular level

[0257] The experiment used Vero E6 cells. Vero E6 cells (50,000 cells / well) were added to a 48-well plate, and 100 μL / well of medium containing gradient concentrations of compounds was added. One hour later, SARS-CoV-2 was added, and the multiplicity of infection (MOI) was 0.01. After 1 hour of co-incubation, the supernatant was aspirated, washed, and 200 μL / well of medium containing gradient concentrations of compounds was added again, and cultured at 37°C for 24 hours. After 24 hours, the cell supernatant was collected, the supernatant viral RNA was extracted, and the supernatant viral copy number was detected by real-time fluorescence quantitative PCR. The compound inhibition rate was calculated based on the viral copy number, and the EC of the compound was calculated using Prism 6.0. 50 .

[0258] The test results showed that compound 2 inhibited the SARS-CoV-2WIV04 strain at a half effective concentration EC 50 The EC of 0.57+ / -0.04μM for inhibiting SARS-CoV-2B.1.351 strain 50 0.73+ / -0.06μM, EC 50 Curve like Figure 1 and 2 shown.

[0259] Example 25-2: Inhibitory effect of compound 2 on SARS-CoV-2 Vero E6 original strain (WIV04), Delta strain (B.1.617.2), and Omicron strain (B.1.1.529) at the cellular level

[0260] Purpose: This study investigated the inhibitory effect of compound 2 on the replication of SARS-CoV-2 original strain (WIV04 strain), Delta strain (B.1.617.2) and Omicron strain (B.1.1.529) in Vero E6 cells by real-time fluorescence quantitative PCR to detect the number of viral copies in the culture supernatant. Since Vero E6 cells highly express the efflux transporter P-gp, 0.5 μM P-gp inhibitor CP-100356 was added and incubated with the compound.

[0261] Experimental Materials:

[0262] Vero E6 was purchased from ATCC (Cat. No. CRL-1586), and the SARS-CoV-2 original strain (SARS-CoV-2-WIV04), Delta strain (B.1.617.2), and Omicron strain (B.1.1.529) were from the Microbial Bacteria (Virus) Collection Center of the Wuhan Institute of Virology, Chinese Academy of Sciences.

[0263] Other reagents are shown in the following table:

[0264]

[0265] Experimental instruments:

[0266] Biological safety cabinet (AC2-3S1, ESCO, Singapore)

[0267] CO2 incubator (Thermo Scientific HERAcell 150i, Thermo Scientific, USA )

[0268] Pure water machine (SYS ultrapure water machine, Chengdu)

[0269] StepOne Plus Real-time PCR system (4376600, ABI, USA)

[0270] TC20 TM Automatic cell counter (1450102, BIO-RAD, USA)

[0271] T100 TM Thermal Cycler (1861096, BIO-RAD, USA)

[0272] Centrifuge (Micro21 / 21R Thermo Scientific, USA)

[0273] Experimental steps:

[0274] Vero E6 cells were digested with trypsin and placed in culture medium (90% DMEM, 10% fetal bovine serum), seeded in 48-well plates, 50,000 cells per well, and cultured overnight. The test compound was dissolved in DMSO to prepare a 40mM stock solution, and further diluted with a culture medium containing 0.5μM Pgp inhibitor to obtain the required concentration for the test. The final concentration range of the test compound in the experiment was 1μM to 0.004μM. The cell supernatant was removed, and the diluted compound (containing 0.5μM Pgp inhibitor) was added to each well and incubated for 1 hour. Different strains of SARS-CoV-2 were added in a biosafety level 3 (BSL-3) laboratory with a multiplicity of infection (MOI) of 0.01 or 0.001. After incubation for 1 hour, the supernatant was removed, washed with PBS, and 200μL / well of the diluted compound (containing 0.5μM Pgp inhibitor) was added. The supernatant was collected 24 or 72 hours after infection. The supernatant viral RNA was extracted and the supernatant viral copy number was detected by real-time fluorescence quantitative PCR. The compound inhibition rate was calculated based on the viral copy number, and the IC of the compound was calculated using GraphPad Prism 8. 50 .

[0275] In the cytotoxicity test, Vero E6 cells were digested and placed in culture medium (90% DMEM, 10% fetal bovine serum), seeded into 96-well plates, 20,000 cells per well, and cultured overnight. The test compound was dissolved in DMSO to prepare a 40mM stock solution, and further diluted with culture medium or culture medium containing 0.5μM Pgp inhibitor to obtain the required concentration for the test. The final concentration range of the test compound in the experiment was 500μM to 1.95μM. The cell supernatant in the 96-well plate was removed, and 100μL / well of the test compound (single drug or containing 0.5μM Pgp inhibitor) was added to the culture medium. After incubation for 24 hours, the cell viability was detected using the CCK8 detection kit, and the inhibition rate and half cytotoxic concentration (CC 50 ).

[0276] Test results: As shown in Table 4, when combined with the P-gp inhibitor CP-100356, compound 2 can inhibit the replication of the Delta strain in Vero E6 cells in a dose-dependent manner, IC 50 The inhibitory effect of compound 2 combined with P-gp inhibitor was 0.040 μM in the original strain. 50 In addition, compound 2 combined with P-gp inhibitors can significantly inhibit the replication of Omicron strain in Vero E6 cells, IC 50 The concentration of compound 2 alone or in combination with P-gp inhibitors had no significant cytotoxicity on the proliferation of VeroE6 cells. 50 >500μM.

[0277] Table 4: Inhibitory effect of compound 2 combined with P-gp inhibitor on SARS-CoV-2 replication in Vero E6 cells

[0278]

[0279] Example 26: In vivo antiviral effect of compound 2 against SARS-CoV-2 Delta strain in hACE2-K18 transgenic mice

[0280] Objective: This study evaluated the antiviral activity of compound 2 against the delta strain of SARS-CoV-2 in K18 transgenic mice stably expressing human angiotensin-converting enzyme 2 (ACE2) (K18-hACE2).

[0281] Experimental Materials:

[0282] K18-hACE2 transgenic mice aged 7-8 weeks were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd. SARS-CoV-2 Delta strain virus was derived from the Microbial Bacteria (Virus) Collection Center of Wuhan Institute of Virology, Chinese Academy of Sciences.

[0283] Ritonavir was purchased from Shanghai Desano Chemical Pharmaceutical Co., Ltd.

[0284] Vero E6 cells were purchased from ATCC (Cat. No. CRL-1586).

[0285] Other reagents are shown in the following table:

[0286]

[0287]

[0288] Experimental instruments:

[0289] Biological safety cabinet (AC2-3S1, ESCO, Singapore)

[0290] CO2 incubator (Thermo Scientific HERAcell 150i, Thermo Scientific, USA )

[0291] Pure water machine (SYS ultrapure water machine, Chengdu)

[0292] StepOne Plus Real-time PCR system (4376600, ABI, USA)

[0293] TC20 TM Automatic cell counter (1450102, BIO-RAD, USA)

[0294] T100 TM Thermal Cycler (1861096, BIO-RAD, USA)

[0295] Centrifuge (Micro21 / 21R Thermo Scientific, USA)

[0296] Tissue grinder (JXFSTPRP-CL, Shanghai Jingxin, China)

[0297] Experimental procedures: K18-hACE2 transgenic mice were infected with SARS-CoV-2 Delta strain by intranasal drops, and this day was day 0. Two hours after infection, the vehicle, 50 mg / kg or 200 mg / kg of compound 2 (combined with 50 mg / kg of cytochrome P450 inhibitor ritonavir) were administered by gavage, and the drug was administered BID for 2 days (including 1 administration on day 0, 2 administrations on day 1, and 1 administration on day 2) or 4 days (including 1 administration on day 0, and 2 administrations on days 1, 2, and 3, respectively). The changes in mouse body weight were recorded, and lung and brain tissues were collected at the end point. Among them, the left lung was fixed with formaldehyde, then embedded, sectioned, and H&E stained for histopathological examination. The right lung and brain tissue were divided into two parts, one of which was ground and the homogenate was taken to extract RNA and reverse transcribed, and the number of viral copies was detected by real-time fluorescence quantitative PCR. The other part was ground and the homogenate was taken to detect the viral titer by plaque assay. The plaque assay method is as follows: Vero E6 cells are seeded in a 24-well plate, 12,000 cells per well, and cultured overnight. The tissue homogenate stock solution is diluted 10 times in DMEM medium for later use. The cell supernatant is removed, the diluted tissue homogenate is added and incubated for 1 hour, then the supernatant is removed, and a medium containing 1% sodium methylcellulose and 2% FBS is added and cultured for 4 days. Then the medium is removed, the cells are fixed with paraformaldehyde, and then stained with 1% (w / v) crystal violet, and the number of plaques in each well is counted.

[0298] Test results: As shown in Table 5, 2 days after infection, compared with the model group (average viral copy number of 9.19±0.30log10copies / g), compound 2 50mg / kg and 200mg / kg significantly reduced the viral load in the lungs in combination with ritonavir, with average copy numbers of 7.66±0.27log10 copies / g and 6.79±0.30log10copies / g, respectively. The viral copy number decreased by 2.4log10 copies / g at a dose of 200mg / kg. After 4 days of infection, a sustained inhibitory effect of compound 2 on viral copy number was observed. In terms of viral titer, Figure 3As shown in the figure, compound 2 had a significant inhibitory effect. After 2 days of infection, the virus replication was completely inhibited at a dose of 200 mg / kg, and the titer was not measured. Compared with the model group, the virus titer decreased by more than 3 log10 PFU / g at a dose of 50 mg / kg. After 4 days of infection, compound 2 showed a sustained inhibitory effect on the virus titer. Figure 4 As shown, 4 days after infection, the body weight of mice in the model group decreased by about 10%, while the body weight of the compound 2-administered group did not decrease significantly, indicating that compound 2 showed no obvious toxicity under continuous administration. We further detected the viral load in the mouse brain, and no obvious infection was found in each group 2 days after infection. 4 days after infection, compared with the model group, compound 2 at doses of 50 mg / kg and 200 mg / kg significantly reduced the number of viral copies in the mouse brain, especially at a dose of 200 mg / kg, the number of viral copies in the brain was comparable to that of the uninfected normal group. We further detected the viral titer in the brain 4 days after infection, and the results are shown in the figure. Figure 5 As shown, compared with the model group, no virus titer was detected at both doses of compound 2, indicating a strong inhibitory effect of compound 2. In addition, histopathological analysis of the lungs showed that compared with the model group, compound 2 at a dose of 200 mg / kg significantly improved lung damage, including reducing the degree of alveolar atrophy or expansion and the degree of alveolar membrane thickening.

[0299] Table 5 Virus load in the lungs and brain of mice 2 and 4 days after infection (mean ± SD)

[0300]

[0301] Example 27: Selectivity of Compound 2 for Kinases

[0302] Experimental purpose: The inhibitory activity of compound 2 against 413 kinases was detected on the KinaseProfile experimental platform to study the selectivity of compound 2 for kinases.

[0303] Experimental Materials:

[0304] Full Human Panel [10uM ATP] Kinase Profiler is a test product provided by Eurofins, item number: 50-005KP10. This product contains 413 kinases.

[0305] Experimental steps:

[0306] Compounds were tested for each selected kinase using the Eurofins standard KinaseProfiler assay and following the relevant standard operating procedures. Protein kinases were detected radiometrically while lipid kinases were detected using HTRF. The ATP concentration in the assay was 10 μM. Detailed information for each kinase is available on the Eurofins website at the following URL: https: / / www.eurofinsdiscoveryservices.com / catalogmanagement / viewItem / Full-Human-Panel-10-uM-ATP-KinaseProfiler / 50-005KP10.

[0307] Experimental results: For 413 kinases, the inhibition rate of compound 2 at a concentration of 10 μM was less than 30%, with no obvious inhibitory effect, indicating that compound 2 has excellent selectivity.

[0308] Example 28: Selectivity of Compound 2 for Safety Targets

[0309] Experimental purpose: The effect of compound 2 on 47 safety-related targets was detected on the Safetyscan experimental platform.

[0310] Experimental Materials:

[0311] Safety47 Panel Dose Response SAFETYscan is a test product provided by Eurofins, with the product number: 87-1003DR. This product contains 78 tests related to 47 safety targets.

[0312] Experimental steps:

[0313] The experimental methods used for 78 tests related to 47 safety targets include: cAMP test, calcium flow test, hormone nuclear receptor test, kinase binding test, enzyme activity test, neurotransmitter transporter test, ion channel test and transporter test. The specific methods of each test can be obtained on the eurofins website at the following URL: https: / / www.eurofinsdiscoveryservices.com / catalogmanagement / viewItem / Safety47-Panel-Dos e-Response-SAFETYscan-DiscoverX / 87-1003DR.

[0314] Experimental results: For 47 safety-related targets, compound 2 had no significant inhibitory or activating effects at a concentration of 100 μM (EC 50All were greater than 100 μM), indicating that compound 2 has excellent selectivity.

[0315] Example 29: Human plasma protein binding test of compound 2

[0316] Experimental Materials

[0317] Human plasma was purchased from BioIVT, anticoagulated with EDTA K2 and stored at -80°C. 96-well equilibrium dialysis plates were purchased from HTDialysis LLC. Equilibrium dialysis membranes were purchased from Gales Ferry.

[0318] Experimental procedures

[0319] Prepare an alkaline solution with a concentration of 14.2 g / L sodium dihydrogen phosphate and 8.77 g / L sodium chloride with ultrapure water. The alkaline solution can be stored at 4°C for 7 days. Prepare an acidic solution with a concentration of 12.0 g / L sodium dihydrogen phosphate and 8.77 g / L sodium chloride with ultrapure water. The acidic solution can be stored at 4°C for 7 days. Titrate the alkaline solution with the acidic solution to a pH of 7.4. The buffer can be stored at 4°C for 7 days. Test the pH of the buffer on the day of the experiment. If it is outside the range of 7.4 ± 0.1, adjust its pH.

[0320] The dialysis membrane was soaked in ultrapure water for 60 minutes to separate the membrane into two pieces, then soaked in 20% ethanol for 20 minutes, and finally soaked in a buffer used for dialysis for 20 minutes.

[0321] Frozen plasma was rapidly thawed at room temperature.

[0322] The plasma was centrifuged at 3,220 g for 10 minutes at 4°C to remove clots, and the supernatant was collected into a new centrifuge tube. The pH value of the plasma was measured and recorded.

[0323] Prepare a 10 mM DMSO stock solution of the substance to be tested. Dilute 2 μL of the stock solution (10 mM) with 98 μL DMSO to obtain a working solution (200 μM). Take 3 μL of the working solution and add 597 μL of human plasma to a final concentration of 1 μM (0.5% DMSO). Vortex thoroughly.

[0324] Add 120 μL of drug-doped plasma sample to one side of the dialysis membrane and an equal volume of dialysate (phosphate buffer) to the other side. The experiment is in parallel. Seal the dialysis plate, put it in the incubator, and incubate it for 6 hours at 37°C, 5% CO2, and about 100 rpm. After the incubation, remove the seal and pipette 50 μL from the buffer and plasma side of each well into different wells of a new plate.

[0325] Add 50 μL of blank plasma to the phosphate buffer sample, and add an equal volume of blank phosphate buffer to the plasma sample. Add 300 μL of room temperature quencher (containing internal standard acetonitrile (IS, 500nM labetalol, 100nM alprazolam and 2μM ketoprofen)) to precipitate the protein. Vortex for 5 minutes. Centrifuge at 3220g for 30 minutes at 4°C. Transfer 100 μL of supernatant to a new plate. Dilute the supernatant with 100 μL or 200 μL of water according to the HPLC response signal and peak shape of the analyte. Mix well and analyze the sample using HPLC.

[0326] All calculations were performed using Microsoft Excel. The peak areas of the test substance on the buffer side and the plasma side were determined. The formula for calculating the plasma protein binding rate of the test substance and the control drug is as follows: free rate = (sample peak area to internal standard peak area ratio buffer side / sample peak area to internal standard peak area ratio plasma side) * 100%, binding rate = 1-free rate, recovery rate = (sample peak area to internal standard peak area ratio buffer side + sample peak area to internal standard peak area ratio plasma side) / (sample peak area to internal standard peak area ratio initial plasma sample) * 100%. The sample peak area to internal standard peak area ratio buffer side represents the free concentration of the compound, the sample peak area to internal standard peak area ratio plasma side represents the sum of the free concentration and the bound concentration of the compound, and the sample peak area to internal standard peak area ratio initial plasma sample represents the total concentration of the compound when the sample begins to incubate.

[0327] Test results:

[0328] See Table 6. 1 μM compound 2 was incubated at 37°C for 6 hours, with an average free rate of 46.63%, a binding rate of 53.37%, and a recovery rate of 88.02%.

[0329] Table 6 Human plasma protein binding test results of compound 2

[0330]

[0331] Example 30: Tissue distribution study of compound 2 by single intragastric administration

[0332] Experimental Materials:

[0333] A total of 60 Balb / c mice (purchased from Shanghai Minchang Biotechnology Co., Ltd.) were used, half male and half female, with a body weight of 18-25 g.

[0334] Experimental steps:

[0335] Balb / c mice were given a single oral administration of compound 2 at a dose of 100 mg / kg in a volume of 10 mL / kg.

[0336] Before and after administration at 5min, 0.25, 1.0, 2.0, 3.0, 5.0, 7.0 and 10h (6 mice at each time point, half male and half female); 0.2ml of blood was collected from the retroorbital venous plexus at the above set time points, placed in an EDTA-K2 test tube, centrifuged at 11000rpm for 5min, plasma was separated, and frozen in a -70℃ refrigerator; lung tissue was collected immediately after whole blood collection at 0.25, 1.0, 3.0 and 7.0h, and the tissue was rinsed with cold saline to remove residual blood and contents on the surface, dried and labeled, and stored at -70℃ for testing. The content of compound 2 in plasma and lung tissue was determined by LC / MS-MS, and the lung-blood ratio was calculated.

[0337] Test results:

[0338] After a single oral administration of compound 2 to Balb / c mice, the ratio of lung tissue exposure to plasma exposure was 0.62, indicating that compound 2 had a high exposure in lung tissue.

[0339] Example 31: Safety pharmacology study on the effect of oral administration of compound 2 on the cardiovascular system of cynomolgus monkeys

[0340] In a 2-week repeated-dose toxicity study in cynomolgus monkeys, the effects of compound 2 on the cardiovascular system were also investigated.

[0341] Experimental Materials:

[0342] Thirty-two cynomolgus monkeys, half male and half female, aged 2.5-5 years old at the time of dosing.

[0343] Source of animals: Yunnan Yingmao Biotechnology Co., Ltd.; Guangxi Xiongsen Primate Experimental Animal Breeding and Development Co., Ltd.; Zhongke Lingrui (Zhanjiang) Biotechnology Co., Ltd.

[0344] Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MBP) of all awake animals were measured using an intelligent non-invasive sphygmomanometer BP-98E, using the Provantis / v10.2.3.1 electronic data acquisition system (PV-02).

[0345] Experimental procedures: 32 cynomolgus monkeys (5 animals / sex / group in Group 1 and Group 4, 3 animals / sex / group in Group 2 and Group 3, a total of 4 groups) were randomly divided into groups and administered with compound 2 (40, 160 and 600 mg / kg / day) or control formulation (98.9% vehicle formulation + 1.1% MTBE, 0 mg / kg / day) by nasogastric administration twice a day for a total of 14 days, and recovered for 14 days after the end of administration. All animals were included in this study to evaluate the effects of administration on ECG parameters (including heart rate, PR interval, QRS duration, QT interval and QTcF) and blood pressure in the pre-drug period, administration period and recovery period.

[0346] Test results: Under the test conditions, crab-eating monkeys were given compound 2 (40, 160 and 600 mg / kg / day) by nasogastric gavage twice a day for 14 days. No test article-related changes in the cardiovascular system were observed; no test article-related arrhythmias were observed; and no test article-related changes in ECG parameters or blood pressure were observed during the entire test.

Claims

1. A cyano compound represented by the general formula I-1 or a pharmaceutically acceptable salt thereof: I-1 in, R 1 Selected from -COR 8 and-SO2R 9 ; R 2 With R 3 Each is independently selected from H, D, C1~C6 alkyl, adamantyl and C3~C7 cycloalkyl; R 6 Selected from and ; R 8 Selected from C1~C6 alkyl, halogenated C1~C6 alkyl, C1~C6 alkoxy, -NR 13 R 14 , C3~C7 cycloalkyl and halogenated C3~C7 cycloalkyl; R 9 Selected from C1~C6 alkyl and C3~C7 cycloalkyl; R 13 and R 14 Each is independently selected from H and C1~C6 alkyl.

2. The cyano compound or a pharmaceutically acceptable salt thereof according to claim 1, wherein R 2 With R 3 Each is independently selected from H, isopropyl, tert-butyl, cyclopentyl and adamantyl.

3. The cyano compound or a pharmaceutically acceptable salt thereof according to claim 2, wherein: R 2 With R 3 One of the groups is selected from H, and the other is selected from isopropyl, tert-butyl, cyclopentyl and adamantyl.

4. The cyano compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein: R 8 Selected from CH3, CF3, CH2CF3, CF2CF3, methoxy, , , cyclopropyl and .

5. The cyano compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, wherein: R 9 Selected from CH3 and cyclopropyl.

6. A cyano compound or a pharmaceutically acceptable salt thereof, wherein the cyano compound is selected from the following compounds: 。 7. A method for preparing a cyano compound represented by general formula I, the method being the following method i: Method I: ia) obtaining a compound represented by formula IV by condensing the compound represented by formula II with the compound represented by formula III; ib) the compound represented by formula IV is dehydrated to obtain the compound represented by general formula I; in, The general formula I in which X is selected from S, Y is selected from S; R 4 With R 5 Connected to each other to form -CH2CH2-, thus connecting X and Y; R 7 Selected from H; R 1 , R 2 , R 3 , R 6 Each as defined in any one of claims 1 to 5.

8. The method according to claim 7, wherein: The step ia) is: the compound represented by formula II is reacted with the compound represented by formula III in a solvent at a temperature of -20°C to 50°C by means of a condensing agent and a base for 0.1-12 hours to obtain the compound represented by formula IV; The solvent is one or a mixture of the following: tetrahydrofuran, dichloromethane, N,N-dimethylformamide, N,N-dimethylacetamide, ethyl acetate, 1,4-dioxane; The condensing agent is one or a mixture of the following: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, 2-hydroxypyridine-N-oxide, 1-propylphosphoric anhydride, 1H-benzotriazole-1-yloxytripyrrolidino hexafluorophosphate, N,N'-carbonyldiimidazole, O-benzotriazole-tetramethyluronium hexafluorophosphate; The base is N,N-diisopropylethylamine, triethylamine or N-methylmorpholine; The step ib) is: the compound represented by formula IV is reacted with a dehydrating agent in an anhydrous solvent at a temperature of -20°C to 50°C for 1-24h to obtain a compound represented by general formula I; The anhydrous solvent is one or a mixture of the following: tetrahydrofuran, dichloromethane, toluene, 1,4-dioxane and pyridine; The dehydrating agent is trifluoroacetic anhydride or N-(triethylammoniumsulfonyl)methyl carbamate.

9. A method for preparing a cyano compound represented by general formula I, the method being the following method ii: Method ii: iia) condensing the compound represented by formula V with the compound represented by formula III to obtain the compound represented by formula VI, wherein PG in the compound represented by formula V is a protecting group of the amino group; iib) deprotecting the compound represented by formula VI to obtain the compound represented by formula VII; iic) the compound represented by formula VII is subjected to aminoacylation, sulfonylation or condensation reaction to obtain the compound represented by formula IV; iid) The compound represented by formula IV is dehydrated to obtain the compound represented by general formula I; in, In the general formula I, X is selected from S, and Y is selected from S; R 4 With R 5 Connected to each other to form -CH2CH2-, thus connecting X and Y; R 7 Selected from H; R 1 , R 2 , R 3 , R 6 Each as defined in any one of claims 1 to 5.

10. The method according to claim 9, wherein: The step iia) is: the compound represented by formula V is reacted with the compound represented by formula III in a solvent at a temperature of -20°C to 50°C by means of a condensing agent and a base for 0.1-12 hours to obtain the compound represented by formula VI; The solvent is one or a mixture of the following: tetrahydrofuran, dichloromethane, N,N-dimethylformamide, N,N-dimethylacetamide, ethyl acetate and 1,4-dioxane; The condensing agent is one or a mixture of the following: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, 2-hydroxypyridine-N-oxide, 1-propylphosphoric anhydride, 1H-benzotriazole-1-yloxytripyrrolidino hexafluorophosphate, N,N'-carbonyldiimidazole and O-benzotriazole-tetramethyluronium hexafluorophosphate; The base is N,N-diisopropylethylamine, triethylamine and N-methylmorpholine; The amino protecting group PG is tert-butyloxycarbonyl, benzyl and p-methoxybenzyl; The step iib) is: reacting the compound represented by formula VI with trifluoroacetic acid or an organic solution of hydrogen chloride or Pd / C / H2 at a temperature of -20°C to 50°C to obtain the compound represented by formula VII; The step iic) comprises: performing an aminoacylation reaction on the compound represented by formula VII and an acid chloride or an acid anhydride under the condition of adding a base at a temperature of -20°C to 50°C to obtain a compound represented by formula IV, or performing a sulfonylation reaction on the compound represented by formula VII and sulfonyl chloride or sulfonic anhydride under the condition of a base at a temperature of -20°C to 50°C to obtain a compound represented by formula IV, or performing a condensation reaction on the compound represented by formula VII and a carboxyl compound under the condition of a condensing agent and a base at a temperature of -20°C to 50°C to obtain a compound represented by formula IV; The base is N,N-diisopropylethylamine, triethylamine and N-methylmorpholine; The condensing agent is one or a mixture of the following: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, 2-hydroxypyridine-N-oxide, 1-propylphosphoric anhydride, 1H-benzotriazole-1-yloxytripyrrolidino hexafluorophosphate, N,N'-carbonyldiimidazole and O-benzotriazole-tetramethyluronium hexafluorophosphate; The step iid) is: the compound represented by formula IV is reacted with a dehydrating agent in an anhydrous solvent at a temperature of -20°C to 50°C for 1-24h to obtain a compound represented by general formula I; The anhydrous solvent is one or a mixture of the following: tetrahydrofuran, dichloromethane, toluene, 1,4-dioxane and pyridine; The dehydrating agent is trifluoroacetic anhydride or N-(triethylammonium sulfonyl) methyl carbamate.

11. A pharmaceutical composition comprising one or more cyano compounds or pharmaceutically acceptable salts thereof selected from any one of claims 1 to 6, and pharmaceutically acceptable excipients.

12. The pharmaceutical composition according to claim 11, wherein The pharmaceutical composition further comprises ritonavir or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical combination comprising one or more selected from the cyano compound or a pharmaceutically acceptable salt thereof as described in any one of claims 1 to 6, and ritonavir or a pharmaceutically acceptable salt thereof.

14. Use of a cyano compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, or a pharmaceutical composition or a pharmaceutical combination according to any one of claims 11 to 13 in the preparation of a drug, wherein the drug is a drug for inhibiting the activity of coronavirus 3CL protease, and the coronavirus is selected from SARS-CoV-2.

15. Use of a cyano compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, or a pharmaceutical composition or a pharmaceutical combination according to any one of claims 11 to 13 in the preparation of a medicament, wherein the medicament is selected from a medicament for treating a coronavirus infection, and the coronavirus is selected from SARS-CoV-2.

16. Use of compound 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament, wherein the medicament is selected from a medicament for treating coronavirus infection, wherein the coronavirus is selected from SARS-CoV, MERS-CoV, H229E-CoV, HKU1-CoV, NL63-CoV and OC43-CoV, Compound 2.